By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

Eli Lilly (NYSE:LLY ... The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it? The order signed on May 12 aims to align U.S. drug prices ...

The president said his executive order will require pharmaceutical companies to price drugs in the U.S. in line with the ...

While pharmaceutical executives raise valid concerns about the lack of detailed implementation plans for the “Most Favored ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...